BostonGene, developer of the leading AI foundation model for tumor and immune biology, today announced the expanded strategic research collaboration with Hokkaido University. This multi-year ...

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) reported revenue ahead of Wall Street’s expectations in Q1 CY2026, ...

Ultimately, Dr. Minn notes, success in immuno-oncology will be measured in multiple ways: Scientifically, by the depth of ...

Daiichi Sankyo aims to transform its antibody-drug conjugate (ADC) leadership into a top global oncology standing. | Daiichi ...

New drugs have made America’s deadliest cancer more treatable than ever. So why aren’t they reaching patients?

Health care policy researcher Nancy Keating discusses two new studies that suggest the short-lived experiment was more ...

CG Oncology CGON reported mixed results for the first quarter on Friday. The company posted quarterly losses of 71 cents per ...

Clinical care remains anchored in disease-specific expertise, but is augmented by wraparound services tailored to life stage.

Coherus Oncology (CHRS) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to a loss of $0.35 per share a year ago. These figures ...

For the first time in its 16-year analysis of the pharma industry, Deloitte found obesity drugs are the largest contributor ...

First results from CORE-008 Cohort CX Phase 2 Trial evaluating intravesical combination therapy in High-Risk BCG-Exposed and BCG-Unresponsive patients to be presented- ...

Heartwarming photos show a San Diego oncology nurse smiling with her father after donating part of her liver to save his life ...